Core Insights - Oxford BioTherapeutics (OBT) has announced a multi-year collaboration with GSK to develop novel antibody-based therapeutics for cancer treatment [1][8] - The collaboration leverages OBT's OGAP®-Verify discovery platform for identifying oncology targets, which will be validated through joint research efforts [2][8] - OBT will receive an undisclosed upfront payment from GSK, along with potential milestone payments and royalties on net sales of resulting products [3][8] Company Overview - OBT is a clinical stage oncology company focused on developing first-in-class antibody-based therapies, including bispecific antibodies and antibody-drug conjugates (ADCs) [5][9] - The company aims to address significant unmet needs in cancer therapy through its innovative drug development approach [5][6] Technology and Development - The OGAP®-Verify platform enhances the sensitivity and specificity of oncology target identification, accelerating the validation of human targets for drug development [6][8] - OBT's lead clinical program, OBT076, targets advanced or refractory solid tumors, with a focus on cancers where CD205 is overexpressed [7][8] Strategic Partnerships - The collaboration with GSK marks OBT's second major partnership with a leading pharmaceutical company in 2025, highlighting the recognition of its discovery platform's potential [4][8] - OBT has previously established partnerships with other major companies, including Roche and Boehringer Ingelheim, validating its capabilities in oncology [8][9]

Crescent Biopharma Conference Call Summary Company Overview - **Company**: Crescent Biopharma - **Focus**: Development of innovative therapies in oncology, particularly in immuno-oncology (IO) and antibody-drug conjugates (ADCs) [2][4] Key Industry Insights - **Market Opportunity**: The oncology market is valued at over $100 billion, with significant potential for innovative therapies [12][44] - **Partnership**: Crescent has formed a strategic partnership with Kelun-Biotech, a leading Chinese biotech company, to advance their pipeline and expand their market reach [9][10] Core Points and Arguments Pipeline Development - **CR001**: A PD-1 VEGF bispecific antibody with the potential to replace Keytruda as a foundational IO therapy. Phase 1/2 studies are set to begin in Q1 2027 [6][7] - **CR002**: A PD-1 topo ADC expected to enter clinical trials in mid-2026 [7][15] - **CR003 (SKB105)**: An integrin beta-6 topo ADC, also on track for early 2026 trials through the partnership with Kelun-Biotech [10][16] Partnership with Kelun-Biotech - **Collaboration Benefits**: The partnership allows for parallel development of CR001 and SKB105, enhancing the clinical data generation across both Western and Chinese patient populations [10][11] - **Kelun's Capabilities**: Kelun-Biotech has a robust pipeline with over 10 clinical-stage assets and established ADC capabilities, which complements Crescent's offerings [9][10] Clinical Strategy - **Combination Studies**: Crescent plans to explore combinations of CR001 with ADCs from both its own pipeline and Kelun's, aiming for multiple clinical data readouts by the end of 2027 [11][31] - **Focus on Key Indications**: The company is targeting thoracic, gastrointestinal, gynecologic, and head and neck cancers, with a strong emphasis on lung cancer due to its large market potential [12][14] Financial Position - **Capital Raise**: Crescent has successfully raised $185 million, positioning the company well for upcoming clinical milestones [8][12] Additional Important Insights - **Innovative Mechanism**: CR001 is designed to replicate the pharmacology of ivonescimab, which has shown promising results in clinical trials, indicating a strong potential for success [21][22] - **Differentiation in ADCs**: Crescent's ADCs, particularly CR002 and CR003, are designed to be best-in-class with unique payloads and mechanisms that enhance efficacy and safety [33][40] - **Regulatory Strategy**: The company is focused on efficient trial designs to accelerate the path to market, leveraging existing clinical data to inform their strategies [26][27] Conclusion Crescent Biopharma is strategically positioned in the oncology market with a robust pipeline and a strong partnership with Kelun-Biotech. The company is focused on innovative therapies that leverage unique mechanisms of action, aiming to deliver transformative treatments for cancer patients. The upcoming clinical trials and data readouts in 2027 are critical milestones for Crescent's growth and market presence [44][45]

Summary of Compugen Conference Call Company Overview - **Company**: Compugen (NasdaqCM:CGEN) - **Industry**: Biotechnology, specifically in immuno-oncology - **Key Focus**: Computational AI-based target discovery for new drug targets Core Points and Arguments 1. **Unique Computational Platform**: Compugen utilizes a validated computational platform to identify first-in-class drug targets in immuno-oncology, including TIGIT and PVRIG [3][4] 2. **Pipeline Assets**: The company has two wholly owned assets, COM-902 (TIGIT blocker) and COM-701 (anti-PVRIG antibody), and has licensed COM-902 to AstraZeneca for use in their bispecific therapy [4][34] 3. **Clinical Trials**: - COM-701 is being evaluated in recurrent platinum-sensitive ovarian cancer, with promising early clinical signals observed, particularly in PD-1 negative patients [5][6][7] - The trial design includes an adaptive approach with a control arm expected to show a median progression-free survival (PFS) of 5.5 months [11][12] - Results from the trial are anticipated in Q1 2027 [12][18] 4. **Biological Mechanism**: PVRIG inhibition is believed to significantly increase T cell presence in the tumor microenvironment, which is critical for efficacy in ovarian cancer [6][9] 5. **Regulatory Considerations**: A three-month improvement in PFS over the control arm could initiate discussions with the FDA regarding accelerated approval due to the unmet need in this patient population [23][24] 6. **Partnership with AstraZeneca**: Compugen has received $30 million in milestones from AstraZeneca and is eligible for an additional $170 million, along with mid-single digit tiered royalties from potential sales of volrustomig [42][44] Additional Important Information 1. **Competitive Landscape**: Compugen is currently the only company with a PVRIG targeting antibody in clinical trials, following GSK's discontinuation of their PVRIG program [28][31] 2. **TIGIT Development**: The company has paused new trials for COM-902 due to ongoing debates in the community regarding TIGIT therapies, but sees future potential based on AstraZeneca's promising results [34][38] 3. **IL-18BP Asset**: Compugen has licensed an IL-18BP blocker to Gilead, which is currently in phase one trials, with a unique mechanism to activate IL-18 in the tumor microenvironment [50][51] 4. **Cash Runway**: Compugen has a cash runway of approximately two years, extending into Q3 2027, allowing for the continuation of current trials without additional income [61] Conclusion Compugen is positioned as a pioneer in computational drug discovery within the immuno-oncology space, with a robust pipeline and strategic partnerships that could lead to significant advancements in cancer treatment. The upcoming trial results and ongoing collaborations will be critical in shaping the company's future trajectory and market position.

Vilastobart Clinical Data and Opportunity - Vilastobart, in combination with atezolizumab, showed a 40% Overall Response Rate (ORR) in MSS mCRC patients without liver metastases and with high plasma TMB[30, 42] - 63% of plasma TMB-evaluable patients had high plasma TMB (≥10 mutations/Mb) in the Phase 2 trial, including all TMB-evaluable responders[32, 33, 42] - A statistically significant correlation (p=0.05) was observed between plasma TMB status and response to vilastobart plus atezolizumab[33, 42] - The combination of vilastobart and atezolizumab demonstrated a differentiated safety profile, with a low discontinuation rate of 5% and only 7% of patients experiencing colitis of any grade[35, 36, 42] Market and Competitive Landscape - Approximately 95% of mCRC patients are MSS, and standard of care in 3L+ provides minimal benefit (1-6% ORR)[23] - Real-world data indicates that approximately 55% of patients with MSS CRC have high plasma TMB, which is substantially higher than historically reported with tissue-based TMB assays[28, 42] - Next-generation anti-CTLA-4 agents in development show promising clinical efficacy in MSS mCRC, with ORRs ranging from 8-29% and discontinuation rates due to AEs up to ~30%[21] Technology and Pipeline - Xilio's clinically-validated platform technology is being applied across diverse mechanisms and architectures, including antibodies, cytokines, bispecifics, and T cell engagers[13, 14] - Efarindodekin Alfa (tumor-activated IL-12) demonstrated promising clinical efficacy with a generally well-tolerated safety profile in Phase 1 in patients with advanced solid tumors[44] - Masked T cell engager programs demonstrated potent anti-tumor activity with favorable tolerability across a diverse range of targets in preclinical models[50, 51, 52] Financial Outlook and Milestones - The company anticipates a cash runway into Q1 2027, including a $175 million development milestone received under the Gilead license in Q4 2025[53] - Anticipated milestones include reporting updated Phase 2 data for vilastobart in combination with atezolizumab in metastatic MSS mCRC in 1H 2026 and IND submissions for at least two masked T cell engager programs in 2027[53]

Summary of Compugen (CGEN) FY Conference Call - September 05, 2025 Company Overview - **Company**: Compugen Ltd. - **Industry**: Clinical-stage immunotherapy, specifically immuno-oncology - **Focus**: Utilizes AI/ML-driven predictive tools for discovering novel drug targets - **Key Collaborations**: Partnerships with AstraZeneca and Gilead [1][3] Core Points and Arguments Development Strategy - Compugen has a rich pipeline with two fully owned clinical assets: COM701 (PVRIG antibody) and COM902 (anti-TIGIT antibody) [3][4] - COM902 is licensed to AstraZeneca for use in a bispecific molecule, relvegostomig, currently in Phase III trials [4] - Gilead is developing GS0321, a potential first-in-class antibody identified through Compugen's Unigen™ platform, now in Phase I study [4][24] Computational Platform - Unigen™ - Unigen™ focuses on target discovery in oncology, identifying novel drug targets to enhance clinical testing options [5] - The platform has been validated through successful transitions from computational predictions to clinical testing [5] COM701 and Ovarian Cancer - COM701 targets PVRIG, which is highly expressed in ovarian cancer, particularly in less inflamed tumor types [6][7] - The MAIA ovarian cancer study aims to evaluate COM701 as a maintenance treatment for platinum-sensitive patients, with a focus on improving progression-free survival [8][14] - Current standard of care for these patients is limited, creating an unmet need that COM701 could address [10][12] Clinical Trial Design - The MAIA study is randomized and blinded, comparing COM701 monotherapy to placebo [14] - Interim analysis expected in H2 2026, with a goal to show improvement in progression-free survival by more than three months [15] TIGIT Development Landscape - Compugen and AstraZeneca continue to evaluate relvegostomig despite challenges faced by other companies in the TIGIT space [20][21] - The unique characteristics of their TIGIT antibody class, which does not bind FC receptors, may contribute to a favorable safety profile [21][22] Financials and Future Outlook - Compugen reported approximately $94 million in cash as of June, providing a runway into 2027 without relying on royalties or milestones from collaborations [31] - Upcoming catalysts include ESMO presentations and readouts from ongoing studies, particularly in the TIGIT landscape [30] Additional Important Content - The partnership with Gilead includes a deal structure worth up to $850 million, with Compugen leading the Phase I study for GS0321 [24][25] - The mechanism of action for GS0321 involves blocking IL-10 binding protein to unleash the activity of IL-10 in the tumor environment [27][28] - The company is optimistic about the potential of COM701 and its ability to prolong the time from platinum-sensitive status to relapse in ovarian cancer patients [12][30]

Financial Data and Key Metrics Changes - In Q2 2025, Coherus Oncology reported net revenue of $10 million, representing a 36% increase quarter-over-quarter and a 65% increase year-over-year [29][37] - The company ended Q2 with $238 million in cash and investments, projecting sufficient cash to provide runway through 2026 [37][38] - Cost savings are expected to reach approximately $30 million on an annualized basis due to headcount reductions [38] Business Line Data and Key Metrics Changes - Lactorsi's net revenue grew 36% over Q1 2025, driven by strong demand from new patients and a positive impact from wholesaler inventory rebuild [29][30] - The number of new purchasing accounts for Lactorsi increased by 20%, indicating broader adoption among physicians [30] Market Data and Key Metrics Changes - The nasopharyngeal cancer market opportunity for Lactorsi is estimated to be between $150 million and $200 million [29][34] - The U.S. market opportunity for casdozoketog in hepatocellular carcinoma is approximately $4 billion, while the potential for CHS-114 in second-line head and neck cancer is about $4.5 billion [34] Company Strategy and Development Direction - Coherus Oncology aims to establish Lactorsi as the standard of care for nasopharyngeal cancer, focusing on educating physicians and expanding market presence [28][30] - The company is pursuing strategic partnerships to enhance its pipeline and expand indications cost-effectively [9][20] - The development strategy includes advancing combination studies across prioritized indications and leveraging collaborations for indication expansion [9][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving revenue goals of $40 million to $50 million for 2025, with a focus on maximizing the nasopharyngeal cancer indication [28][34] - The company anticipates key data readouts in the first half of 2026, which are expected to validate their pipeline and support future growth [41][44] Other Important Information - Coherus Oncology completed a strategic repositioning and renamed the company to better reflect its mission in oncology [5] - The company is the only independent U.S. biotech developing a CCR8 Treg depleter, which is expected to have significant market potential [14] Q&A Session Summary Question: Importance of identifying a partner for the CCRA program - Management indicated that they are actively seeking partners to accelerate progress and offset development costs, with data readouts expected in the first half of next year [46][47][49] Question: Confidence in reaching revenue goals for Lactorsi - Management expressed confidence in achieving peak revenues by 2028, supported by strong uptake following NCCN guideline updates [52][54] Question: Competitive landscape for anti CCR8 and anti IL-27 programs - Management noted that there are currently no known competitors in clinical development for anti IL-27, while the anti CCR8 program is seeing robust development activity [58][60][61] Question: Community engagement strategy - The company is focusing on a multi-pronged approach to engage community oncologists, anticipating that peak sales will take three to four years due to the dispersed nature of patient management [66][67] Question: Enrollment progress for casdozoketog trials - Management confirmed that recruitment is going well in both the U.S. and Asia Pacific regions, with data expected in the first half of next year [74][75] Question: Impact of guidelines on community adoption - Management highlighted that while academic centers have adopted the guidelines quickly, community oncologists require ongoing education to integrate the guidelines into practice [96][98]

Financial Data and Key Metrics Changes - Total company revenues for Q2 2025 were approximately $12.3 billion, reflecting strong demand across the business [20] - The growth portfolio saw a 17% year-over-year increase in sales, primarily driven by demand for key brands [7][21] - Diluted earnings per share was reported at $1.46, which includes a charge of approximately $1.5 billion related to the BioNTech partnership [30] Business Line Data and Key Metrics Changes - Opdivo global sales were approximately $2.6 billion, up 7%, driven by demand in the U.S. and international markets [21] - REBLOZYL global sales reached $568 million in the quarter, with a 30% growth in the U.S. and a 46% increase outside the U.S. [24] - BRYANZI revenues grew 122% globally, reflecting strong demand across all indications [25] - Kamsiyos global sales were $260 million, growing 86% due to robust demand [26] - Eliquis global sales were $3.7 billion, growing 6% [27] Market Data and Key Metrics Changes - The U.S. market saw strong launches for both Opdivo and KEVANTIC, with the latter receiving a permanent J code to support reimbursement [22][23] - The company expects the legacy portfolio to decline approximately 15% to 17% for the year, a more moderate rate than previously anticipated [32] Company Strategy and Development Direction - The company is focused on reshaping for long-term sustainable growth, with strategic partnerships announced with BioNTech and PhiloChem to enhance its oncology and radiopharmaceutical capabilities [8][12] - The company is entering a data-rich period with seven registration assets and seven lifecycle management opportunities expected in the next 12 to 24 months [14] - The company aims to drive improved growth in the outer years and attractive returns for shareholders through strategic business development initiatives [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential despite some studies not meeting expectations, emphasizing the importance of upcoming data readouts [39] - The company is optimistic about the performance of its growth portfolio and has raised its full-year revenue guidance by $700 million [32] - Management highlighted the importance of maintaining a strong pipeline and the potential for new therapies to address unmet medical needs [100] Other Important Information - The company is committed to returning capital to shareholders through dividends while also focusing on debt reduction, aiming to pay down $10 billion by 2026 [31] - A new Executive Vice President, Chief Medical Officer, and Head of Development will join the company, indicating a focus on advancing the pipeline [19] Q&A Session Summary Question: Insights on Phase III results and potential for line extensions - Management noted that while some studies did not yield expected results, they do not foresee significant long-term impacts on growth and are optimistic about future opportunities [39][40] Question: Context on direct-to-consumer offering with Pfizer - The partnership aims to increase patient access and affordability, cutting out middlemen in the healthcare system [48][51] Question: Launch dynamics and hurdles for COBENFI - The launch is tracking as expected, with positive physician feedback and plans to expand into hospital settings [59][60] Question: Rationale for partnering with BioNTech - The partnership is seen as a strategic move to enhance the growth profile and leverage both companies' strengths in immuno-oncology [68][71] Question: Competitive dynamics for KAMZIOS - The company remains confident in KAMZIOS's growth potential despite upcoming competition, emphasizing its established efficacy and safety profile [89] Question: Insights on MILVEXIAN's potential - Management believes there is an underappreciation of MILVEXIAN's differentiated dosing and its potential to address significant unmet needs in various indications [99][100]

Financial Data and Key Metrics Changes - Total company revenues for Q2 2025 were approximately $12.3 billion, reflecting strong demand across the business [19] - The growth portfolio saw a 17% year-over-year increase in sales, primarily driven by demand for key brands [5][19] - Gross margin was approximately 73%, primarily due to product mix, with operating expenses down by approximately $260 million compared to the same period last year [29][30] - Diluted earnings per share was $1.46, which includes a $1.5 billion charge related to the BioNTech strategic partnership [30][34] Business Line Data and Key Metrics Changes - Opdivo global sales were approximately $2.6 billion, up 7%, driven by demand in the U.S. and international markets [20] - REBLOZYL global sales were $568 million in the quarter, with U.S. revenue growth up 30% year-over-year [22] - BRYANZI revenues were $344 million, reflecting a 122% increase due to strong demand across all indications [25] - Kamsiyos global sales were $260 million, growing 86% due to robust demand [26] - Eliquis global sales were $3.7 billion, growing 6% primarily due to strong demand [27] Market Data and Key Metrics Changes - In the U.S., Opdivo revenues were approximately $1.5 billion, largely driven by a strong launch in MSI high colorectal cancer [20] - Outside the U.S., Opdivo revenues grew 7%, driven by volume growth and one-time favorable adjustments [20] - REBLOZYL sales outside the U.S. grew 46%, reflecting continued demand across newly launched markets [23] Company Strategy and Development Direction - The company is focused on reshaping for long-term sustainable growth, optimizing its cost structure, and enhancing its growth portfolio [5][19] - Strategic partnerships with BioNTech and Philochem aim to strengthen immuno-oncology and radiopharmaceutical capabilities [6][11] - The company is prioritizing investments in areas with the strongest potential for high-value assets [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential despite some studies not meeting expectations, emphasizing the importance of upcoming data readouts [39] - The company is entering a data-rich period with seven registration assets and seven lifecycle management opportunities expected in the next 12 to 24 months [13] - Management raised full-year revenue guidance by $700 million, reflecting strong performance and better-than-expected legacy sales [32][34] Other Important Information - The company announced a direct-to-consumer offering for Eliquis in partnership with Pfizer, aimed at increasing patient access and affordability [45][49] - A new Executive Vice President, Chief Medical Officer, and Head of Development will join the company, indicating a focus on pipeline advancements [17] Q&A Session Summary Question: Upcoming data-heavy period and Phase III results - Management acknowledged the importance of upcoming studies and their limited impact on long-term growth, emphasizing confidence in future opportunities [39] Question: Macro pressures and direct-to-consumer offering - The direct-to-consumer offering was implemented to cut out middlemen and provide patients with lower costs and increased transparency [46][49] Question: Launch dynamics for COBENFI - COBENFI is performing in line with expectations, with steady growth anticipated as the company expands its prescriber base [56] Question: Competitive dynamics for Kamsiyos - Management remains confident in Kamsiyos' growth despite upcoming competition, citing strong real-world data and positive feedback on label changes [86] Question: Differentiation of MILVEXIAN - Management believes there is an underappreciation of MILVEXIAN's differentiated dosing and its potential in multiple indications [90][92]

Financial Data and Key Metrics Changes - As of March 31, 2025, the company had approximately $103.7 million in cash, cash equivalents, total bank deposits, and investments in marketable securities [16] - Revenues for Q1 2025 were approximately $2.3 million, a decrease from approximately $2.6 million in Q1 2024 [17] - R&D expenses for Q1 2025 were approximately $5.8 million, down from approximately $6.4 million in Q1 2024 [17] - The net loss for Q1 2025 was approximately $7.2 million, or $0.08 per basic and diluted share, compared to a net loss of approximately $7.3 million in the same period of 2024 [17] Business Line Data and Key Metrics Changes - The company is advancing its clinical immunotherapy pipeline, particularly focusing on the anti-PVRIG antibody COM701, with a sub-trial initiated for patients with relapsed platinum-sensitive ovarian cancer [7][8] - The study aims to demonstrate a three-month improvement over the median progression-free survival compared to placebo, which would be clinically meaningful [9] Market Data and Key Metrics Changes - AstraZeneca has initiated multiple Phase III trials in the TIGIT space, with significant potential revenue opportunities estimated at over $5 billion in lung cancer alone [11] - The eligible lung cancer patient population across G7 countries is estimated to exceed 500,000 patients based on 2025 epidemiological data [11] Company Strategy and Development Direction - The company is focused on advancing its early-stage and clinical immuno-oncology pipeline while ensuring a cash runway into 2027 [5][14] - The leadership transition aims to provide a solid foundation for the company's next growth phase [5][6] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential impact of their clinical trials on cancer patients' lives and emphasized the importance of their innovative pipeline [14][15] - The company is committed to advancing its clinical assets and early-stage research pipeline while maintaining a solid balance sheet with no debt [16] Other Important Information - The company has established strategic collaborations and built a robust management team to support its growth initiatives [5] - The clinical trial landscape is evolving, with a focus on the potential advantages of COM701 in the maintenance setting of platinum-sensitive ovarian cancer [9] Q&A Session Summary Question: Impact of Merck's KEYNOTE B96 trial success on the company's strategy in ovarian cancer - Management noted that while Merck's trial is in platinum-resistant ovarian cancer, their study focuses on platinum-sensitive patients, and positive results could open up additional opportunities for COM701 [21][22] Question: Interpretation of Roche's Skyscraper one data regarding TIGIT - Management discussed the challenges faced in the trial and emphasized the importance of patient population and statistical design in interpreting the results [24][26] Question: Data collection on tumor microenvironment features from the COM701 study - The company confirmed that it will collect data to evaluate the tumor microenvironment, with a focus on PVRIG expression and IFN signatures [31] Question: Activity in PD-L1 positive patients and potential combinability with other treatments - Management indicated that they have seen activity in both PD-L1 positive and negative patients, suggesting potential for COM701 in various settings [36][38]

Core Insights - iTeos Therapeutics is advancing its clinical-stage immuno-oncology therapeutics, with significant interim data expected from multiple studies in 2025, including GALAXIES Lung-201 and GALAXIES H&N-202 [1][2][4] - The company reported a cash balance of $624.3 million as of March 31, 2025, which is anticipated to support operations through 2027 [1][9] - iTeos is focused on generating differentiated clinical data to support the advancement of its product candidates, particularly the belrestotug + dostarlimab combination therapy [2][3] Financial Performance - For Q1 2025, iTeos reported R&D expenses of $29.0 million, a decrease from $34.5 million in Q1 2024, attributed to the phasing of belrestotug studies and the discontinuation of the inupadenant program [9] - General and Administrative (G&A) expenses were $11.0 million for Q1 2025, down from $12.7 million in Q1 2024, primarily due to reduced stock-based compensation and professional fees [9] - The net loss for Q1 2025 was $34.6 million, or $0.80 per share, compared to a net loss of $38.2 million, or $1.07 per share, in Q1 2024 [9] Product Development - The belrestotug (EOS-448/GSK4428859A) is being developed for first-line treatment of advanced non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) in collaboration with GSK [3][8] - EOS-984 is a potential first-in-class small molecule targeting ENT1, aimed at inhibiting adenosine's immunosuppressive effects [4][10] - EOS-215 is a monoclonal antibody targeting TREM2, designed to reprogram the tumor microenvironment [5][11] Upcoming Milestones - Topline interim data from the GALAXIES Lung-201 study, involving over 240 patients, is expected in Q2 2025, with data to be presented at a scientific congress in the second half of 2025 [4][9] - Interim data from the GALAXIES H&N-202 study, assessing belrestotug + dostarlimab in HNSCC, is anticipated in 2025 [4][9] - The company is also progressing with the EOS-984 and EOS-215 programs, with data expected in the latter half of 2025 [9]